| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 11 | 2021 | 140 | 2.720 |
Why?
|
| Prostatic Neoplasms | 8 | 2025 | 1092 | 2.390 |
Why?
|
| Leptin | 9 | 2021 | 118 | 2.240 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 163 | 2.190 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2020 | 25 | 2.150 |
Why?
|
| Adenocarcinoma | 9 | 2010 | 291 | 1.900 |
Why?
|
| Exons | 5 | 2025 | 92 | 1.810 |
Why?
|
| Fibronectins | 4 | 2020 | 69 | 1.800 |
Why?
|
| Liver Neoplasms | 9 | 2023 | 224 | 1.730 |
Why?
|
| Cell Line, Tumor | 26 | 2025 | 2676 | 1.440 |
Why?
|
| Up-Regulation | 6 | 2025 | 536 | 1.400 |
Why?
|
| Gallic Acid | 2 | 2022 | 11 | 1.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2025 | 968 | 1.330 |
Why?
|
| Apoptosis | 16 | 2020 | 1568 | 1.290 |
Why?
|
| Liver Neoplasms, Experimental | 3 | 2015 | 22 | 1.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2021 | 299 | 1.270 |
Why?
|
| Cell Proliferation | 14 | 2025 | 1455 | 1.230 |
Why?
|
| Barrett Esophagus | 5 | 2009 | 29 | 1.160 |
Why?
|
| Cyclooxygenase 2 | 9 | 2019 | 107 | 1.070 |
Why?
|
| Gastrins | 4 | 2009 | 9 | 1.060 |
Why?
|
| Hepatitis B | 3 | 2023 | 41 | 0.950 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 512 | 0.950 |
Why?
|
| Neuroendocrine Tumors | 1 | 2025 | 11 | 0.900 |
Why?
|
| Humans | 51 | 2025 | 43102 | 0.890 |
Why?
|
| Neoplasms | 5 | 2023 | 1377 | 0.890 |
Why?
|
| Signal Transduction | 10 | 2025 | 2157 | 0.890 |
Why?
|
| Adiponectin | 4 | 2013 | 59 | 0.850 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2013 | 19 | 0.840 |
Why?
|
| Pancreatic Neoplasms | 4 | 2020 | 218 | 0.810 |
Why?
|
| Janus Kinase 2 | 6 | 2013 | 36 | 0.780 |
Why?
|
| GTP Phosphohydrolases | 2 | 2021 | 34 | 0.770 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2021 | 11 | 0.720 |
Why?
|
| New York City | 5 | 2023 | 288 | 0.670 |
Why?
|
| Plasmacytoma | 1 | 2020 | 11 | 0.660 |
Why?
|
| Glioblastoma | 1 | 2021 | 74 | 0.660 |
Why?
|
| Cell Movement | 7 | 2025 | 655 | 0.650 |
Why?
|
| Oncogene Protein v-akt | 2 | 2012 | 20 | 0.650 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 25 | 0.650 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 307 | 0.640 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 56 | 0.630 |
Why?
|
| Receptors, Oxytocin | 1 | 2019 | 9 | 0.630 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 140 | 0.620 |
Why?
|
| Gene Dosage | 1 | 2019 | 75 | 0.620 |
Why?
|
| Oxytocin | 1 | 2019 | 24 | 0.620 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 237 | 0.610 |
Why?
|
| Cell Division | 4 | 2008 | 311 | 0.600 |
Why?
|
| Male | 17 | 2025 | 23409 | 0.570 |
Why?
|
| Enzyme Activation | 9 | 2021 | 462 | 0.570 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 228 | 0.560 |
Why?
|
| Cell Separation | 2 | 2015 | 94 | 0.560 |
Why?
|
| Mice, Inbred BALB C | 6 | 2019 | 694 | 0.540 |
Why?
|
| Colonic Neoplasms | 4 | 2011 | 223 | 0.530 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2006 | 84 | 0.530 |
Why?
|
| RNA, Small Interfering | 7 | 2020 | 436 | 0.530 |
Why?
|
| Emigrants and Immigrants | 1 | 2019 | 158 | 0.530 |
Why?
|
| Diet | 2 | 2022 | 826 | 0.520 |
Why?
|
| Vaccination | 1 | 2019 | 355 | 0.520 |
Why?
|
| Transcription Factors | 1 | 2021 | 735 | 0.500 |
Why?
|
| Epithelial Cells | 1 | 2019 | 434 | 0.490 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 144 | 0.460 |
Why?
|
| Translocation, Genetic | 3 | 2020 | 40 | 0.440 |
Why?
|
| Mice | 10 | 2020 | 6644 | 0.430 |
Why?
|
| Animals | 16 | 2020 | 16992 | 0.410 |
Why?
|
| MicroRNAs | 2 | 2017 | 518 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 9 | 0.400 |
Why?
|
| Sulfonamides | 7 | 2011 | 91 | 0.390 |
Why?
|
| NF-kappa B | 4 | 2008 | 358 | 0.380 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 1596 | 0.370 |
Why?
|
| STAT3 Transcription Factor | 3 | 2013 | 102 | 0.360 |
Why?
|
| Prognosis | 4 | 2020 | 861 | 0.350 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2019 | 652 | 0.340 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 11 | 0.320 |
Why?
|
| Epoprostenol | 1 | 2010 | 28 | 0.320 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 291 | 0.320 |
Why?
|
| Prostate | 2 | 2023 | 155 | 0.320 |
Why?
|
| Pyrazoles | 5 | 2010 | 103 | 0.320 |
Why?
|
| Cadherins | 3 | 2019 | 102 | 0.310 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2007 | 41 | 0.300 |
Why?
|
| Obesity | 2 | 2008 | 1151 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2019 | 165 | 0.290 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2011 | 98 | 0.290 |
Why?
|
| Intestinal Mucosa | 2 | 2007 | 134 | 0.280 |
Why?
|
| Dinoprostone | 4 | 2012 | 64 | 0.280 |
Why?
|
| Receptors, Adiponectin | 1 | 2008 | 5 | 0.280 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2008 | 18 | 0.280 |
Why?
|
| RNA, Messenger | 4 | 2019 | 1271 | 0.270 |
Why?
|
| Cell Line | 3 | 2019 | 1410 | 0.270 |
Why?
|
| Phosphorylation | 5 | 2011 | 986 | 0.260 |
Why?
|
| Acids | 1 | 2007 | 19 | 0.260 |
Why?
|
| Gastrointestinal Agents | 1 | 2007 | 6 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 89 | 0.260 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 100 | 0.260 |
Why?
|
| Endothelial Cells | 1 | 2010 | 329 | 0.250 |
Why?
|
| Phosphotransferases | 1 | 2006 | 36 | 0.250 |
Why?
|
| Disease Progression | 3 | 2019 | 667 | 0.250 |
Why?
|
| Colitis | 1 | 2007 | 71 | 0.240 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 51 | 0.240 |
Why?
|
| Female | 8 | 2023 | 24698 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2019 | 257 | 0.230 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1234 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 200 | 0.230 |
Why?
|
| Adipose Tissue | 1 | 2006 | 182 | 0.220 |
Why?
|
| Aged | 4 | 2022 | 8214 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 290 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 189 | 0.210 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 518 | 0.200 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2009 | 28 | 0.200 |
Why?
|
| Gene Expression | 2 | 2019 | 701 | 0.200 |
Why?
|
| Cell Differentiation | 2 | 2020 | 638 | 0.200 |
Why?
|
| Hepatitis B, Chronic | 1 | 2023 | 16 | 0.200 |
Why?
|
| HT29 Cells | 3 | 2007 | 60 | 0.180 |
Why?
|
| Cause of Death | 1 | 2023 | 186 | 0.180 |
Why?
|
| Databases, Genetic | 2 | 2019 | 103 | 0.180 |
Why?
|
| tRNA Methyltransferases | 1 | 2021 | 1 | 0.180 |
Why?
|
| Cytokines | 1 | 2006 | 678 | 0.180 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 5 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 508 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2021 | 21 | 0.180 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 22 | 0.180 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 147 | 0.180 |
Why?
|
| Vimentin | 2 | 2012 | 44 | 0.180 |
Why?
|
| Vegetables | 1 | 2022 | 147 | 0.170 |
Why?
|
| Methyltransferases | 1 | 2021 | 68 | 0.170 |
Why?
|
| Risk Factors | 2 | 2019 | 3994 | 0.170 |
Why?
|
| Fruit | 1 | 2022 | 178 | 0.160 |
Why?
|
| Epidermal Growth Factor | 2 | 2012 | 70 | 0.160 |
Why?
|
| Africa | 1 | 2019 | 82 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 116 | 0.150 |
Why?
|
| Endostatins | 1 | 2019 | 5 | 0.150 |
Why?
|
| Mollusk Venoms | 1 | 2019 | 23 | 0.150 |
Why?
|
| RNA | 1 | 2021 | 266 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2019 | 17 | 0.150 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 32 | 0.150 |
Why?
|
| Middle Aged | 3 | 2019 | 12222 | 0.150 |
Why?
|
| Survival Rate | 1 | 2019 | 355 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 145 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 39 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 518 | 0.140 |
Why?
|
| Feeding Behavior | 1 | 2022 | 469 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 502 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 638 | 0.140 |
Why?
|
| Liver | 2 | 2019 | 511 | 0.140 |
Why?
|
| Hospitalization | 1 | 2021 | 485 | 0.140 |
Why?
|
| Mutation | 2 | 2019 | 1177 | 0.140 |
Why?
|
| RNA Interference | 2 | 2009 | 247 | 0.130 |
Why?
|
| Cell Survival | 3 | 2013 | 945 | 0.130 |
Why?
|
| Tyrphostins | 2 | 2008 | 15 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2021 | 2544 | 0.130 |
Why?
|
| Receptors, Leptin | 2 | 2007 | 14 | 0.130 |
Why?
|
| Cell Membrane | 1 | 2019 | 403 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 760 | 0.130 |
Why?
|
| Logistic Models | 1 | 2019 | 1009 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 333 | 0.120 |
Why?
|
| Transcriptional Activation | 2 | 2008 | 173 | 0.120 |
Why?
|
| Interleukin-8 | 2 | 2007 | 74 | 0.120 |
Why?
|
| Age Factors | 1 | 2019 | 1154 | 0.120 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 146 | 0.120 |
Why?
|
| Peptides | 1 | 2019 | 372 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2006 | 105 | 0.120 |
Why?
|
| Mass Screening | 1 | 2019 | 541 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 139 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 706 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 33 | 0.100 |
Why?
|
| Mesoderm | 1 | 2013 | 73 | 0.100 |
Why?
|
| Models, Biological | 2 | 2013 | 712 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 18 | 0.100 |
Why?
|
| Niacinamide | 1 | 2012 | 16 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2853 | 0.100 |
Why?
|
| Cell Transplantation | 1 | 2012 | 4 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 2 | 2013 | 49 | 0.090 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 7 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2012 | 35 | 0.090 |
Why?
|
| Albumins | 1 | 2012 | 33 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 45 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1081 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 34 | 0.090 |
Why?
|
| Models, Animal | 1 | 2011 | 151 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 97 | 0.090 |
Why?
|
| Base Sequence | 1 | 2013 | 983 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 863 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3156 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 590 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 152 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 526 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2011 | 238 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1542 | 0.080 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 7 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 989 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 458 | 0.080 |
Why?
|
| Imidazoles | 2 | 2011 | 142 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2013 | 403 | 0.080 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2009 | 4 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2011 | 883 | 0.070 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2008 | 8 | 0.070 |
Why?
|
| RNA Stability | 1 | 2008 | 28 | 0.070 |
Why?
|
| Young Adult | 1 | 2019 | 5080 | 0.070 |
Why?
|
| Pravastatin | 1 | 2008 | 6 | 0.070 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2008 | 8 | 0.070 |
Why?
|
| Lovastatin | 1 | 2008 | 9 | 0.070 |
Why?
|
| Adolescent | 1 | 2019 | 6081 | 0.070 |
Why?
|
| Mevalonic Acid | 1 | 2008 | 12 | 0.070 |
Why?
|
| Okadaic Acid | 1 | 2008 | 16 | 0.070 |
Why?
|
| Nitrobenzenes | 1 | 2008 | 19 | 0.070 |
Why?
|
| Simvastatin | 1 | 2008 | 29 | 0.070 |
Why?
|
| Sesquiterpenes | 1 | 2008 | 38 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2008 | 181 | 0.070 |
Why?
|
| Multienzyme Complexes | 1 | 2008 | 69 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 38 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2008 | 100 | 0.070 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2008 | 68 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2008 | 139 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2008 | 227 | 0.070 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2007 | 20 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 31 | 0.070 |
Why?
|
| Dextran Sulfate | 1 | 2007 | 19 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2008 | 125 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2008 | 139 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2008 | 117 | 0.060 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 2 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 575 | 0.060 |
Why?
|
| Maleimides | 1 | 2006 | 12 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 14 | 0.060 |
Why?
|
| Anthracenes | 1 | 2006 | 15 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 39 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 34 | 0.060 |
Why?
|
| Adult | 2 | 2019 | 13872 | 0.060 |
Why?
|
| Sulfones | 1 | 2006 | 47 | 0.060 |
Why?
|
| Isoquinolines | 1 | 2006 | 55 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 458 | 0.060 |
Why?
|
| Nitriles | 1 | 2006 | 81 | 0.060 |
Why?
|
| Morpholines | 1 | 2006 | 72 | 0.060 |
Why?
|
| Tyrosine | 1 | 2006 | 120 | 0.060 |
Why?
|
| Chromones | 1 | 2006 | 53 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2006 | 195 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 145 | 0.060 |
Why?
|
| Flavonoids | 1 | 2006 | 100 | 0.060 |
Why?
|
| Pyridines | 1 | 2006 | 139 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 168 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 137 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2006 | 95 | 0.060 |
Why?
|
| Minority Groups | 2 | 2023 | 690 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1124 | 0.060 |
Why?
|
| Research Design | 1 | 2007 | 385 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 347 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2019 | 456 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2006 | 201 | 0.050 |
Why?
|
| Indoles | 1 | 2006 | 187 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 18 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2007 | 1621 | 0.050 |
Why?
|
| Mentors | 1 | 2023 | 145 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2005 | 561 | 0.040 |
Why?
|
| Rats | 1 | 2008 | 3735 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2020 | 27 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 63 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 74 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 121 | 0.030 |
Why?
|
| New Jersey | 1 | 2017 | 15 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2017 | 43 | 0.030 |
Why?
|
| Vietnam | 1 | 2017 | 62 | 0.030 |
Why?
|
| Hawaii | 1 | 2023 | 2011 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 241 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 220 | 0.030 |
Why?
|
| Genomics | 1 | 2016 | 293 | 0.030 |
Why?
|
| Antibodies, Immobilized | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 83 | 0.020 |
Why?
|
| raf Kinases | 1 | 2012 | 7 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 90 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2012 | 48 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 54 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 158 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 245 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2011 | 28 | 0.020 |
Why?
|
| Naphthoquinones | 1 | 2011 | 41 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2011 | 80 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 154 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 47 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 523 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 83 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 174 | 0.010 |
Why?
|
| United States | 1 | 2016 | 5205 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1019 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 934 | 0.010 |
Why?
|